Microsoft downgraded on AI competition concern Microsoft (MSFT) was downgraded by DA Davidson to Neutral from Buy, citing the ...

Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands ...

Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...

Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...

Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its ...

The S&P 500 added 0.3% on Monday, Sept. 23, notching a record close as positivity from last Wednesday's interest-rate cut ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Adds Wells Fargo analyst comment. Regeneron Pharmaceuticals (NASDAQ:REGN) quickly dropped 3.5% after a judge denied the ...